All stock lists
Apogee Therapeutics, Inc. (APGE)
United States · Delayed Price · Currency is USD
Biological Products, (No Diagnostic Substances)
135.07
Insider Score
––Not scored
APGE Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
APGE Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| SG&A Expense | 24.01 M | 21.62 M | 19.28 M | 16.77 M | 17.14 M | — |
| R&D Expense | 67.30 M | 60.82 M | 58.44 M | 54.18 M | 55.70 M | — |
| Operating Expenses | 91.64 M | 82.77 M | 78.06 M | 71.28 M | 73.17 M | — |
| Operating Income | -91.64 M | -82.77 M | -78.06 M | -71.28 M | -73.17 M | — |
| Pretax Income | -85.78 M | -74.03 M | -69.33 M | -64.96 M | -66.02 M | — |
| Tax Provision | 78.00 K | 79.00 K | 62.00 K | 61.00 K | 72.00 K | — |
| Net Income | -85.85 M | -74.11 M | -69.39 M | -65.02 M | -66.10 M | — |
| EPS (Basic) | -1.14 | -1.06 | — | -1.08 | -1.11 | -0.93 |
| EPS (Diluted) | -1.14 | -1.06 | — | -1.08 | -1.11 | -0.93 |
| Shares Outstanding | 75.44 M | 69.67 M | — | 60.15 M | 59.59 M | 59.53 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.